Positive bird flu vaccine data drives Novavax shares; EMA supports Eli Lilly's Amyvid for Alzheimer's diagnosis;

Conversations on Twitter :

 @FierceBiotech: Wanted: Premier hepatitis C drug developer to partner with Vertex. More | Follow @FierceBiotech

 @JohnCFierce: $1.2B in VC for biotech in Q3 not the best ever, but a whole lot more than we've been seeing--so I see it as a solid +. More | Follow @JohnCFierce

> Shares of Novavax ($NVAX) got a boost out of the news that two early-stage studies of its bird flu vaccine produced positive results. Story

> The EMA is recommending approval of Eli Lilly's ($LLY) Amyvid, a radioactive dye that can be used to help clinicians diagnose Alzheimer's. Story

> Chapel Hill, NC-based Cempra says it raised $25 million from the sale of shares. The biotech will earmark much of that to fund clinical trials. Release

> Histogen is touting early-stage evidence of efficacy for its "Hair Stimulating Complex." Release

Pharma News

@FiercePharma: More drug payment/pricing action in Greece. Some brand meds said to be struck from formulary. Article | Follow @FiercePharma

> Actavis CEO: Biosims market will be tough to crack. Report

> GSK CEO remains 'a huge bull on India.' Story

> EMA committee shoots down Vivus diet pill. Article

Medical Device News

 @FierceMedDev: VC investment in Q3 is way down for medical devices. More | Follow @FierceMedDev

 @MarkHFierce: So what were the top med device VC deals in the 2012 third quarter? More | Follow @MarkHFierce

 @DamianFierce: Steris is spending $110M on M&A to expand its surgical device capabilities. More | Follow @DamianFierce

> Complete Genomics scores patent win over Illumina. Story

> Study: To reduce heart disease risks, gastric banding beats drugs. News

> Sony slashes jobs on road to medical device focus. Item

And Finally… In a new study published in Nature, scientists point to mutations in neural stem cells as a likely new suspect involved in the hunt to determine what triggers Parkinson's disease. Story


Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.